Serum brain-derived neurotrophic factor as a predictor of anxiolytic response: A randomized comparison of desvenlafaxine and escitalopram in depression with comorbid anxiety
Perspectives in Clinical Research · 20.05.2026
DOI: 10.4103/picr.picr_323_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Perspectives in Clinical Research, online erschienen am 20.05.2026. Verfasst von Chaitali A Chindhalore und 4 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Introduction
Selective serotonin reuptake inhibitors act primarily on serotonin, whereas serotonin–norepinephrine reuptake inhibitors (SNRIs) modulate both serotonin and norepinephrine, potentially influencing their anxiolytic effects. Brain-derived neurotrophic factor (BDNF), a key mediator of neuroplasticity, may play a role in anxiety reduction, but comparative data across antidepressants remain limited.
Objective
To compare the effects of desvenlafaxine and escitalopram on anxiety and somatic symptoms, examine correlations between serum BDNF and anxiety improvement, and evaluate whether BDNF predicts reduction in anxiety symptoms in patients with major depressive disorder (MDD) with comorbid anxiety. Methodology: In this randomized, open-label, parallel-group study (CTRI/2021/11/038260), patients with MDD (Hamilton Rating Scale for Depression [HAM-D] 8-23) and comorbid anxiety (Hamilton Anxiety Rating Scale [HAM-A] >17) received desvenlafaxine 50 mg ( n = 20) or escitalopram 10 mg ( n = 19) daily for 8 weeks. Depression, anxiety, and somatic symptoms were assessed using HAM-D, HAM-A, and somatic symptom scale-8 (SSS-8) scales. Serum BDNF was measured at baseline and week 8. Multiple regression included age, sex, and baseline HAM-A as covariates.
Results
Of 54 screened, 39 patients completed the study. Both treatments significantly improved HAM-D, HAM-A, and SSS-8 scores. Desvenlafaxine showed greater improvement in somatic symptoms ( P = 0.012) and a higher rise in BDNF (113.5 ± 97.0 vs. 57.4 ± 70.7 pg/ml). In the desvenlafaxine group, BDNF change correlated strongly with HAM-A reduction ( r = −0.69, P = 0.001) and independently predicted anxiety improvement (β = −0.66, R 2 =0.50, P = 0.003).
Conclusion
Only desvenlafaxine demonstrated a predictive relationship between BDNF increase and anxiety reduction, supporting BDNF’s potential as a biomarker for SNRI response.
Zitieren
APA
Chindhalore, C. A., Jaiswal, S. V., Dakhale, G. N., Gajbhiye, S. V., & Bhoyar, A. (2026). Serum brain-derived neurotrophic factor as a predictor of anxiolytic response: A randomized comparison of desvenlafaxine and escitalopram in depression with comorbid anxiety. Perspectives in Clinical Research. https://doi.org/10.4103/picr.picr_323_25
Vancouver
Chindhalore CA, Jaiswal SV, Dakhale GN, Gajbhiye SV, Bhoyar A. Serum brain-derived neurotrophic factor as a predictor of anxiolytic response: A randomized comparison of desvenlafaxine and escitalopram in depression with comorbid anxiety. Perspectives in Clinical Research. 2026. doi:10.4103/picr.picr_323_25
BibTeX
@article{Chindhalore2026,
author = {Chindhalore, Chaitali A and Jaiswal, Suyog Vijay and Dakhale, Ganesh N and Gajbhiye, Snehalata V and Bhoyar, Apurva},
title = {Serum brain-derived neurotrophic factor as a predictor of anxiolytic response: A randomized comparison of desvenlafaxine and escitalopram in depression with comorbid anxiety},
journal = {Perspectives in Clinical Research},
year = {2026},
doi = {10.4103/picr.picr_323_25}
}
EUVIMED